A new study from researchers at Mayo Clinic has found a promising way to improve how doctors detect testicular cancer, especially in cases that are difficult to identify using current methods.
The findings were published in the journal Nature Communications and suggest that a new type of blood test could make diagnosis faster and more accurate.
Testicular cancer is the most common cancer in young men, particularly affecting teenagers and adults in their 20s and 30s. The good news is that it is usually highly treatable, especially when it is found early. However, early detection is not always easy.
Doctors often rely on blood tests that look for specific substances known as tumor markers. These markers are chemicals released by cancer cells into the blood.
When they are present at high levels, they can help doctors confirm a diagnosis. But not all tumors produce enough of these markers. In some cases, the levels are too low to be detected, which can delay diagnosis and treatment.
To address this problem, the Mayo Clinic research team developed a new approach. Instead of looking for just a few markers, they analyzed thousands of signals from the immune system at the same time. The immune system responds to changes in the body, including the presence of cancer, and these responses can leave detectable patterns in the blood.
Using this advanced method, the researchers created a test called GCT-iSIGN. This test looks for patterns in immune signals that are linked to germ cell tumors, which are the most common type of testicular cancer.
The team tested this new method using 427 blood samples. The results were very encouraging. The test correctly identified 93 percent of people who had germ cell tumors.
It also correctly showed that 99 percent of people without cancer did not have the disease. Even more importantly, the test was able to detect 23 out of 24 cancer cases that standard blood tests had missed.
This means the new test could give doctors a powerful additional tool, especially when traditional methods do not provide clear answers. It may be particularly helpful for younger patients, who are most often affected by this type of cancer.
The researchers also developed a second test, called Sem-iSIGN. This test helps doctors tell the difference between the two main types of testicular cancer. This distinction is important because each type may require a different treatment plan. Being able to identify the exact type of cancer can help doctors choose the most effective treatment more quickly.
This research builds on earlier work by the same team. In previous studies, they used similar immune-based techniques to identify markers linked to a rare condition associated with testicular cancer. One such marker, called KLHL11 IgG, was previously described in The New England Journal of Medicine.
According to Dr. Divyanshu Dubey, the senior author of the study, current testing methods can sometimes fall short. When standard tumor markers are negative, doctors may face delays in confirming a diagnosis and deciding on treatment. The new approach could help overcome this challenge by providing a more sensitive way to detect cancer.
Although the results are promising, the researchers caution that more studies are needed before the test can be used in everyday medical practice. Larger clinical trials will be required to confirm its accuracy and usefulness in different patient groups.
Even so, this study represents an important step forward. By using the body’s immune signals as a guide, scientists are opening new possibilities for earlier and more reliable cancer detection. If further research confirms these findings, this type of blood test could help doctors diagnose testicular cancer sooner and improve outcomes for patients.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Copyright © 2026 Knowridge Science Report. All rights reserved.
